Aug 11, 2014 Sanofi and Mankind announce partnership to market Afrezza . First week of February 2015 official launch. If I'm not mistaken they(Sanofi and Mankind) had 6 months from the time of partnership announcement till official launch date to set up appointments, and plan for FEV test and equipment.
I love hearing all the different theories that it is taking so long because they have to educate the MD's. I just got done watching a 25 second video on how Afrezza is so easy even a 5 year old can do it. Now if a 5 year old is showing how easy it is to use in a 25 second video how long do you think it would take to educate an individual that has made it through Med school? The chart that shows it's pharmakinetics takes all of 3 to 5 seconds to interpret. The video of Al Mann at John Hopkins explaining the history of Afrezza , how it works and how to use it takes less then 10 minutes. I think we are doing a big injustice to all the MD's in the U.S. if we are reporting that it will take a long time to educate the MD's.
If there were multiple companies working up bids for MNKD would MNKD keep it silent. I think yes. If Sanofi was not 100% sure they could secure all of MNKD would they be advertising like crazy now only to try and figure later how to tell the public they lost out in a bidding war. Only time will tell.
For the smart ones yes. I know Nurses, Occupational therapists, Physical therapists and MD's and the ones I have spoken to the answer is yes.
Having the price as low as it is will allow the MD's to issue free samples, talk to the pt's about their experiences and when the MD's hear and see the results they will be blown away. It only takes 5 minutes to place a buy order in for a stock. This price will allow the Md's to load up then once they have, BOOM here comes the commercials and advertising blitz.
If you know know who Peter Lynch is and have read his books you might enjoy hearing this again. If you don't know who Peter Lynch is you might learn from it. Here is the quote, "It isn't the head but the stomach that determines the fate of the stockpicker. The skittish investor, no matter how intelligent, is always susceptible to getting flushed out of the market by the brush beaters of doom".
Knowing this has served me very well in the past and I have to give credit to Peter.
You are comparing apples to watermellons. How many free Exubera samples and expensive free large bongs were handed out with Exubera launch. My guess is slim to none.
Yes, but you are leaving out the patients that do not ask for samples but want a RX filled right away. Now you have to factor those into your numbers.
Sanofi has to deal with GS and all the other shorting institutions all the time. They have many drugs they peddle. In the end GS and other shorting institutions will own hundreds of millions if not billions worth of their stock and their partners stock. It might be better to wait silently in the shadows then stab them in the back. Sanofi and MNKD know what they have and this is just a temporary dip in the road.
The shorts can read conference call transcripts, they can watch social media videos, they can read Afrezzauser blogs, they can watch Al Mann presentations, they know everything the longs know. When the potentially best selling drug ever is being handed out for free and they still have time to steal shares why wouldn't they, after all it is Wallstreet!
Forget the first couple weeks/months script numbers because the shorts will conjure up all sorts of the "Sky is Falling" articles that will scare some of the less experienced investors into selling regardless if the numbers are poor, good or great.
IT IS IMPORTANT THAT WE LONG TERM INVESTORS:
1)Follow the science(pharmokinetics).
2) The real users experiences(Afrezzauser and others like him).
3)Sanofi's experience in getting a drug out globally.
5)Al Mann's experience/proven successes.
6)Follow the Money(Blackrock and the other big institutions they seem to have done extremely well for themselves over the years).
Al Mann's billion on the line, real Afrezza users testimonials in videos and Sanofi's asking for more samples in CC is all I need to know. If you are worried sell.
Just one question. If administration and dosing process takes 4 to 6 months why is it Adam Lasher appears to be doing better with Affrezza then his injections during his first week on his free sample. Adam was not in the trials yet his learning curve is less then 1 week? He is starting from scratch and his video states how well he is doing during his first week!.
The institutions continue to add, Al is not selling, retail continues to add and shorts continue to short. When you do the math you realize that time is running out and something is going to give very soon. Kevin says not till June but the share count says sooner.
This reminds me of when Henry Ford first started making cars. If Henry would have given out his first 10,000 cars free for 10 days how many people would have gone back to riding a horse or walking after those 10 days? When electricity first came out if the electric company would have given out free electricity for 10 days how many people would have gone back to candles and oil lamps? We are sitting on a goldmine with
Afrezza. Stay thirsty longs, buy, buy, buy.
When Blackrock SEC filing(acquiring 5%) came out on 2/6/15 the volume of shares traded that day were 7 million for MNKD. There was not one one media press release that day about them acquiring 5% of the company(that is 10's of millions of shares). Compare that to GS who owned only 600K shares who puts out a press release with no real meat to back up their downgrade and the stock trades 22 million shares that day ending with a 7% drop in price and an inter day drop as high as 13.5%. There were also 11 press releases today from multiple sources all stating to stay away from MNKD for now. In summary, TOTALLY SKEWED!
The price droped 24 cents the other night in after hours on 14,000 shares. The shorts would have been better off trading 30K shares in after hours.
Does this make sense, your company owns 626,513 shares of MNKD as of 12/31/14 and your company has recently purchased 400,182 shares on the quarter ending 12/31/14. Now if you are an analyst working for the company and you really feel a stock you own is a bad investment do you 1)sell shares in the open market at 6.64 per share and get rid of your shares then issue a down grade after you have sold your shares or do you 2)Issue a down grade and drop the price .49 cents per share then sell your shares and cost the company you work for (.49) x 626,513 = $306,991. The 3rd option is 3)You issue a downgrade hold on to your 626,513 shares get the price to drop 7 to 13.5% and buy a ton more because you listened to the recent MNKD conference call and the management states"Our free samples given out exceeded Sanofi's expectations and we need to supply Sanofi with more samples". My guess is the analyst for GS decided to keep his job by choosing #3 which will make his company a boat load of money in the long run Options #1 and #2 would only get him fired.
Interesting 14,000 shares to take the price down 26 cents. That means if there are 90,000,000 shares short and for every 14,000 shares it is worth 26 cents then when the shorts cover the price will go up by 90,000,000 divided by 14,000 = 6,428 x 0.26 = 1,671 Wow, so when the shorts cover their 90 million shares the price per share should go up 1,671 dollars per share assuming it works the same way up as down.